It was the most difficult year since its establishment due to Corona 19. We are building hope by overcoming well with the support of shareholders and the generous support and support of the people concerned.

I hope you are all the fine.

Corona 19, which was expected to be settled early, expanded and continued to be a pendemic, and a vaccine was released, but I am worried that it will take a considerable amount of time to normalize.

In the midst of difficult and difficult, on March 25, 2020, in the process of demonstrating the administration of anticancer drugs with the existing pump at Uijeongbu St. hospital, we found out that the existing pump was not guaranteed the accurate injection of anticancer drugs and that in the process of administering anticancer drugs with anyfusion pump with guaranteed accuracy, anticancer drugs with strong toxicity were diluted (prepared) with glucose or physiological saline.

Most of the dispensing is based on information that a person who is a pharmacist dispenses manually with a syringe or dispenses with a robot.

We have found that the cylinder cartridge, which is the core technology of the cylinder pump, which has changed the linear motion of the syringe to the rotational motion, has no exposure to toxic substances, and is a source technology that can be manufactured using a machine (cylinder pump) rather than a human or robot.

We immediately prepared a patent application, applied for a patent on May 13th, and started development, informing the pharmacist, the user of each hospital, to increase the degree of development completion based on various feedbacks and at the time of patent registration on October 25, we completed the manual ACPi development and prepared the approval from the Ministry of Food and Drug Safety. We passed the technical document in December, and in early January 2021 (next week), with the approval of the Ministry of Food and Drug Safety, the development and sale of accessories and assembly machines were completed. If there is no problem after testing, we would like to start demo.

Unlike Anyfusion pump, ACPi and APiS are habitual or familiar with existing products, so there is no alternative, no comparison target, no competition, and The world's only and first ACPi (manual) that must adapt to new technology products is released in January 2021, so we believe that to our shareholders and stakeholders who have supported and helped us, we will achieve our goal with hope and opportunity in a difficult situation with Corona 19.

In January 2021, according to the user's response to passive ACPi, the ACPi direction and potential, as well as its potential, are likely to be measured. Depending on the results in Korea, it is expected to become a bridgehead for not only advanced countries but also overseas markets. In Korea, it is developing into a smart stage of advanced IoT solution system as well as ICT (HIS), which is already active.However, Anyfusion platform items (pharmaceutical, pump, PCA, BTP, etc.), ICT and IoT solutions are built into the advanced smart system, which will enter the market from the beginning and establish itself as a leading technology product that is the center of the market. Developed countries such as the United States, Japan, Germany, the United Kingdom, and France are preparing to enter the market as soon as the corona ends as local subsidiaries. ACPi and APiS are not only an important turning point for the company, but also for those concerned with generous support, as well as innovative and breakthrough technologies that escape from dangerous difficult environments for those who have to risk and handle the risk of toxicity. It is expected that the quality and environment will improve and will even play a role as a great transformation.

ACPi (Anti Cancer Priparation and Infusion) is the only machine that automatically prepares and injects anticancer drugs like an automated machine in a factory by driving the cylinder cartridge, the core source technology, with a cylinder pump equipped with electric, electronic and mechanical elements. With the integrated ApiS (Automatic Preparation to injection System), which includes automatic preparation and injection of injections in the ward, ward, and intensive care unit, is a smart solution for HIS-linked IoT system that focuses on users and places of use. We would like to repay our shareholders and related people for sending us.

MCSTD optimized for ACPi and APiS will replace CSTD which is used in 28 countries and is a consumable product with a market size of 5 trillion won per year. MCSTD has developed even core technologies for universal use in the ward, and intends to market the middle and underdeveloped countries. In January-February, a video about passive ACPi and MCSTD is completed and released on the website and YouTube, and when introduced to users, rapid market expansion is expected and I am confident that we will become the first mover in the infusion market.

We wish all the supportive shareholders and the families of all of the people involved in health and a Happy New Year.

Thank you.